Allspring Global Investments Holdings LLC Increases Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Allspring Global Investments Holdings LLC raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 5.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 599,116 shares of the company’s stock after purchasing an additional 30,092 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 1.82% of TransMedics Group worth $94,061,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas bought a new stake in TransMedics Group during the 3rd quarter valued at $55,000. J.Safra Asset Management Corp lifted its position in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the period. Finally, Fidelis Capital Partners LLC purchased a new position in shares of TransMedics Group in the first quarter valued at $35,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX stock opened at $126.60 on Monday. The firm has a market cap of $4.22 billion, a P/E ratio of 3,165.00 and a beta of 1.99. The firm’s fifty day moving average is $152.70 and its 200 day moving average is $138.75. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same period last year, the firm earned ($0.03) earnings per share. The company’s revenue for the quarter was up 117.7% compared to the same quarter last year. Research analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Oppenheimer boosted their price objective on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Needham & Company LLC began coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price on the stock. Robert W. Baird assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 price target for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a report on Monday, October 7th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $174.30.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,205 shares of company stock worth $9,981,907 in the last ninety days. 7.00% of the stock is owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.